Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
May 9, 2014 7:00 AM EDTBEDMINSTER, N.J. and DUBLIN, Ireland, May 9, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operations.
Key Amarin achievements since December 31, 2013 include:
Recognized $11.0 million in product revenue from Vascepa® (icosapent ethyl) sales in Q1 2014 compared to $2.3 million in Q1 2013 Increased productivity company-wide by advancing key initiatives, with lower cost and staffing levels than previous quarters, while maintaining Vascepa prescription... More